Monoclonal antibodyFDA-approvedSecond-line
Nivolumab
How it works
Blocks PD-1, a protein that normally helps cancer cells evade the immune system, allowing the immune system to attack cancer cells.
Cancer types
Lung Cancer— All patients
Colorectal Cancer— All patients
Pancreatic Cancer— All patients
Ovarian Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median overall survival of approximately 9.2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing IL2 and Immunotherapy in Advanced Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab with Standard Treatment for Colorectal Cancer with BRAF Mutation | Colorectal Cancer | phase-2 | — | Source → |
| Melanoma Treatment Trial Investigates Combination of NeoVax and Immunotherapies | Melanoma | phase-1 | — | Source → |
| Evaluating Nivolumab and Ipilimumab in Combination with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Immunotherapy May Offer Better Survival for Lung Cancer Patients with Poor Health | Lung Cancer | phase-3 | Median overall survival was significantly longer with nivolumab: 29-weeks (95% CI: 11.3-46.7) versus 8-weeks (95% CI: 3.5-12.5; p<0.001) | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer and Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma That Has Progressed | Melanoma | phase-3 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Low-dose nivolumab shows promise in treating lung cancer | Lung Cancer | phase-2 | The estimated 2-year event-free survival rate was 56.1% (95% confidence interval [CI]: 38.3%-73.9%), and the 2-year disease-free survival rate was 66.6% (95% CI: 56.4%-86.8%). | Source → |
| Testing Nivolumab to Prevent Leukemia Relapse | Leukemia | phase-2 | — | Source → |
| Testing a New Treatment for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Nivolumab and Ipilimumab with Radiation in Advanced Rectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Trial Tests Cancer Drugs in HIV Patients | Breast Cancer | phase-1 | — | Source → |
| Nivolumab and Ipilimumab Trial | Lung Cancer | phase-2 | — | Source → |
| Testing Immunotherapy After Surgery for High-Risk Melanoma | Melanoma | phase-3 | — | Source → |
| Testing Tocilizumab with Immunotherapy for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Immunotherapy Shows Promise for Rare Ovarian and Cervical Cancers | Leukemia | phase-2 | The overall response rate was 9.38%, with two complete responses that are ongoing at >3 years and one partial response. | Source → |
| Nivolumab's Safety and Effectiveness in Chinese Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 21.2 months. | Source → |
| B cells and genetic changes may predict response to cancer treatment | Ovarian Cancer | phase-2 | More than two passenger fusion genes were detected in six of the seven responders, whereas eight of the ten non-responders lacked fusion genes. | Source → |
| GRIm Score Predicts Response to Melanoma Treatment | Melanoma | observational | Patients with a low GRIm Score had significantly longer median progression-free survival (21.4 vs. 6.3 months, p = 0.003) and overall survival (26.5 vs. 7.2 months, p < 0.001). | Source → |
| Combining Immunotherapy for Advanced Anal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 2.9 months for nivolumab and 3.7 months for nivolumab plus ipilimumab. | Source → |
| Long-term remission in lung cancer patient treated with nivolumab | Lung Cancer | observational | The patient remained in continuous remission with a progression-free survival exceeding 82 months and an overall survival exceeding 84 months. | Source → |
| Combining TM5614 and Nivolumab to Treat Advanced Melanoma | Melanoma | phase-3 | — | Source → |
| New Biomarker Predicts Outcomes for Lung Cancer Patients on Nivolumab | Lung Cancer | observational | Patients with GLR <70.76 achieved significantly longer OS (median 24.1 vs 9.6 months; p < 0.001) and PFS (9.7 vs 5.8 months; p < 0.001) compared with those with GLR ≥70.76. | Source → |
| Rare Side Effect of Cancer Treatment in Older Patient | Melanoma | observational | — | Source → |
| Immunotherapy Response Predicted by Low Tumor Mutation Burden and PD-L1 Expression | Melanoma | observational | — | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| New Study Explores Using Nivolumab to Treat Malignant Ascites | Pancreatic Cancer | phase-2 | Seven patients (77.8%) showed a clinical response. | Source → |
| Melanoma Study Examines Vaccine Combination with Immunotherapy | Melanoma | phase-2 | Objective response rates were 59.7% and 59.2% in the two treatment arms. | Source → |
| Combining Nivolumab with Chemotherapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | Fifteen of the 20 evaluable patients had complete gross resection at ICS, and 7 of 20 achieved an optimal pathologic chemotherapy response score of 3. | Source → |
| Immune therapy may trigger severe colitis in some patients | Melanoma | observational | — | Source → |
| Combination Treatment Shows Promise for Rare Gynecological Cancers | Ovarian Cancer | phase-2 | The overall objective response rate was 54% (95% CI, 35-71), with 3 (12%) complete responses and 12 (42%) partial responses. | Source → |
| Study Examines Combination Therapy for Advanced Liver Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Cost-effectiveness of dual immunotherapy for lung cancer | Lung Cancer | phase-3 | Nivolumab plus ipilimumab provided an incremental gain of 1.11 and 0.96 QALYs over chemotherapy in the USA and China, respectively. | Source → |
| Comparing Two Ways to Give Cancer Treatment | Melanoma | phase-2 | — | Source → |
| Long-term Survival and Response to Immunotherapy in Melanoma Patients | Melanoma | phase-2 | At 4 years from the start of treatment, 80% of patients remained event-free, including 95% of patients who achieved a major pathologic response. | Source → |
| Combining RP1 and Nivolumab May Help Some Melanoma Patients | Melanoma | phase-2 | The confirmed objective response rate was 32.9% (95% CI, 25.2% to 41.3%; 15.0% complete response). | Source → |
| Rare Side Effect of Cancer Treatment: Tongue Discoloration | Ovarian Cancer | observational | — | Source → |
| TIL Therapy for Melanoma Patients May Benefit from IFNα Support | Melanoma | phase-2 | Disease control was obtained in 11.1% of the patients treated without IFNα and in 41.7% of the patients treated with IFNα. | Source → |
| Combination Therapy Improves Survival in Advanced Melanoma Patients | Melanoma | preclinical | The 4-year progression-free survival rate was 30.6% for nivolumab plus relatlimab versus 23.6% for nivolumab alone. | Source → |
| Combination Therapy Shows Promise for Metastatic Uveal Melanoma | Melanoma | observational | — | Source → |
| Color Vision Loss in Melanoma Patient Treated with Nivolumab-Relatlimab | Melanoma | observational | — | Source → |
| Nivolumab Treatment in Melanoma Patients: Immune and Nutritional Status Linked to Survival | Melanoma | observational | Patients with high HALP scores had significantly longer progression-free survival (PFS: median 5.8 vs 3.1 months) and overall survival (OS: median 54.9 vs 14.4 months) compared to those with low HALP scores. | Source → |
| Combining Telaglenastat and Nivolumab in Cancer Treatment | Melanoma | phase-1/2 | The overall response rate was 8.4% in the response-assessable analysis set. | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Nivolumab Effectiveness in Non-Small Cell Lung Cancer | Lung Cancer | observational | The 36-month OS rate was 19.7% (95% confidence interval [CI] 17.5-22.0); the 12-month investigator-assessed best ORR in the overall population was 20.4%. | Source → |
| Inflammatory Markers and Metastases Predict Nivolumab Response in Lung Cancer | Lung Cancer | observational | The median overall survival was 21.2 months (95% CI: 17.4-25.0). | Source → |
| Brazilian Study Examines Cost of New Melanoma Treatments | Melanoma | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.